 Evaluation oral dosages ondansetron prevention nausea emesis cyclophosphamide-doxorubicin chemotherapy antiemetic efficacy safety different oral doses ondansetron GR novel serotonin receptor antagonist consecutive series breast cancer patients cyclophosphamide-doxorubicin-based chemotherapy first time Patients oral doses mg mg mg ondansetron times days first minutes cyclophosphamide infusion efficacy conventional antiemetic regimen intravenous lorazepam metoclopramide chemotherapy mg prochlorperazine study day times study day fourth series patients comparable characteristics number emetic episodes assessment nausea appetite adverse events study period Pretreatment posttreatment clinical laboratory data emesis study period patients ondansetron doses patients conventional therapy incidence intensity nausea doses ondansetron conventional group Ondansetron-related side effects mild reversible dose-dependent manner effects headache stomach cramps diarrhea fatigue serum transaminase concentrations patient mg doses ondansetron tremors muscle twitching Oral ondansetron effective safe antiemetic patients noncisplatin cyclophosphamide-doxorubicin-based chemotherapy antiemetic activity dose-related